What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Another Take on the 2022 EULAR RA Treatment Guidelines
Dr. Peter Nash reviews the new 2022 EULAR RA Treatment Guidelines, presented at #EULAR2022.
Watch video →
EULAR 2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
Watch video →
2022 ASAS/EULAR Recommendations on the Management of Axial Spondyloarthritis
Dr. Peter Nash discusses the new ASAS/EULAR Spondyloarthritis treatment guidelines presented at EULAR 2022
Watch video →
RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
Dr. Jonathan Kay reports on RA-related sessions and abstracts from day 1 at EULAR 2022.
Watch video →
New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force.
Watch video →
EULAR 2022 - Day 1 Faculty Recap Panel
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at EULAR 2022 - Guidelines, Lupus, and more.
Watch video →
Dr. John Cush RheumNow
3 years 2 months ago
Study of Adult-onset Still's in Western Australia. Incidence = 0.22/100 000, prevalence = 2.4/100 000. AOSD had higher risk of previous liver disease (OR 2.67), serious infx (OR 4.36), joint replacement (OR 45.5), mortality not increased @ 1 & 5 yrs https://t.co/Wu0SQIMjWT https://t.co/Zvsdb2OR0y
Data from Data FORWARD (The National Databank for Rheumatic Diseases) reveals that nearly two-thirds of rheumatoid arthritis (RA) patients have self-reported sleep problems.
The FORWARD study, a registry that includes over 4200 RA patients), collects data on obstructive sleep apnea (OSA), restless legs syndrome (RLS), and short sleep (SS) problems. SS was based on self-reported average sleep time (<6 hours).
Dr. John Cush RheumNow
3 years 2 months ago
Autoimmune Disease Augments Cardiovascular Risk
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
https://t.co/TtiH9ZBkR8 https://t.co/jVZBk8l4XD
Still's disease in adults (AOSD) or children (sJIA) can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed (for clinical trial and treatment assessments). A new study compares two such activity measuresin a large cohort of Still's patients.
Dr. John Cush RheumNow
3 years 2 months ago
Review of cGAS/STING - enzyme cyclic GMP-AMP synthase. self genomic & mitochondrial DNA stimulates cGAS-->dimerizes & binds to the endoplasmic reticulum protein stimulator of IFN genes (STING), unleashing an inflammatory response https://t.co/g04v1S4PYJ https://t.co/SHeneZq4sd
Dr. John Cush RheumNow
3 years 2 months ago
Review of IL-1 inhibitors in recurrent idiopathic pericarditis. While Rilonacept is FDA approved (320 mg x1 then 160 mg sc/wk), anakinra (2 mg/kg/d or 100 mg/d), canakinumab and colchicine are used https://t.co/EQJV4qTFPj https://t.co/Rdkn4ljh0X
Dr. John Cush RheumNow
3 years 2 months ago
USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/XEaXqcCEg1 https://t.co/vEqEFV1kYv
Dr. John Cush RheumNow
3 years 2 months ago
Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
- Steroid use "for irAEs may not have a large deleterious effect on overall survival"
- DMARDs for irAE "a major drawback in the delay in the onset of response"
https://t.co/YciXN4fdZQ https://t.co/oNgszsYNB8
Dr. John Cush RheumNow
3 years 2 months ago
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/4Hew7zVu7J https://t.co/za9hQ8Plnl
Dr. John Cush RheumNow
3 years 2 months ago
Prospective study of 124 adults hospitalized w/ acute MSK trauma saw good outcomes in 23% @6 mos & 61% @12 mos. Worse outcomes assoc w/ posttraumatic stress Sxs (OR 2.09), pain intensity (2.87), # fractures (2.79)& pain extent (4.67) https://t.co/ubuyWCBFgU https://t.co/ZfNGUQ1i0e
Research presented in the Journal of Experimental Medicine shows that ANCA-associated vasculitis (AAV) may be propagated by pathogenic mechanisms triggering cGAS/STING/IRF3-dependent IFN-I release.
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
Dr. John Cush RheumNow
3 years 2 months ago
Influenza Vaccination Recommendations
The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.
https://t.co/6V21XZUsqX https://t.co/ln9bqta6UT
Dr. John Cush RheumNow
3 years 2 months ago
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/lSvnAkRvxB https://t.co/i7ZORYyKHP
Dr. John Cush RheumNow
3 years 2 months ago
The prospective CARDIA cohort study studied 2110 adults (38 - 50 yrs) for 10+ yrs and showed those taking >7000 steps/day had a 50% to 70% lower risk of mortality (vs those taking <7000 steps/day). https://t.co/lE152z8vTw https://t.co/hjfnCN4bno
Poster Hall